Advisors Asset Management Inc. Purchases 853 Shares of Amedisys Inc (NASDAQ:AMED)

Advisors Asset Management Inc. lifted its position in shares of Amedisys Inc (NASDAQ:AMED) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,277 shares of the health services provider’s stock after acquiring an additional 853 shares during the period. Advisors Asset Management Inc. owned approximately 0.10% of Amedisys worth $5,706,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Mutual of America Capital Management LLC increased its position in shares of Amedisys by 0.9% during the fourth quarter. Mutual of America Capital Management LLC now owns 29,013 shares of the health services provider’s stock valued at $4,843,000 after acquiring an additional 252 shares in the last quarter. Voya Financial Advisors Inc. grew its position in Amedisys by 10.1% in the 3rd quarter. Voya Financial Advisors Inc. now owns 4,890 shares of the health services provider’s stock worth $631,000 after purchasing an additional 447 shares during the period. Voya Investment Management LLC grew its position in Amedisys by 9.8% in the 3rd quarter. Voya Investment Management LLC now owns 601,676 shares of the health services provider’s stock worth $78,825,000 after purchasing an additional 53,618 shares during the period. Credit Suisse AG grew its position in Amedisys by 59.9% in the 4th quarter. Credit Suisse AG now owns 44,482 shares of the health services provider’s stock worth $7,426,000 after purchasing an additional 16,660 shares during the period. Finally, Stifel Financial Corp grew its position in Amedisys by 15.1% in the 3rd quarter. Stifel Financial Corp now owns 16,033 shares of the health services provider’s stock worth $2,098,000 after purchasing an additional 2,101 shares during the period. 89.83% of the stock is owned by institutional investors.

A number of equities research analysts have commented on AMED shares. SunTrust Banks lifted their target price on shares of Amedisys from $185.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $215.00 target price on shares of Amedisys in a research report on Friday, February 21st. They noted that the move was a valuation call. UBS Group lifted their target price on shares of Amedisys from $154.00 to $208.00 and gave the stock a “neutral” rating in a research report on Friday, February 21st. Stephens lifted their target price on shares of Amedisys from $180.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Friday, February 21st. Finally, Raymond James lifted their target price on shares of Amedisys from $200.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday, February 20th. Five equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Amedisys has a consensus rating of “Buy” and a consensus target price of $182.86.

In related news, Director Teresa L. Kline purchased 1,000 shares of the firm’s stock in a transaction on Monday, March 16th. The shares were acquired at an average price of $142.63 per share, for a total transaction of $142,630.00. Following the purchase, the director now directly owns 1,780 shares in the company, valued at $253,881.40. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Bruce D. Perkins purchased 2,000 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was bought at an average price of $153.16 per share, for a total transaction of $306,320.00. Following the purchase, the director now owns 25,385 shares in the company, valued at $3,887,966.60. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,000 shares of company stock worth $635,950 and sold 23,129 shares worth $4,439,923. 2.90% of the stock is owned by insiders.

AMED opened at $161.71 on Thursday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.07 and a current ratio of 1.07. Amedisys Inc has a fifty-two week low of $106.65 and a fifty-two week high of $202.76. The firm’s fifty day moving average is $179.90 and its 200 day moving average is $159.73. The stock has a market cap of $5.44 billion, a price-to-earnings ratio of 42.22, a price-to-earnings-growth ratio of 2.36 and a beta of 1.39.

Amedisys (NASDAQ:AMED) last released its earnings results on Tuesday, February 18th. The health services provider reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.01. The company had revenue of $500.70 million for the quarter, compared to analysts’ expectations of $511.58 million. Amedisys had a net margin of 6.49% and a return on equity of 24.95%. Amedisys’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.91 EPS. On average, equities research analysts predict that Amedisys Inc will post 5.02 earnings per share for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

See Also: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply